Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 13/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 11/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721674 | 0.86 | SYK (0.40) | ROCK2ROCK1CDC42BPBSYKAURKB | |
| SCHEMBL15210404 | 0.86 | SYK (0.40) | ROCK2ROCK1CDC42BPBSYKAURKB | |
| SCHEMBL15210347 | 0.77 | MAPK1 (0.35) | SYK | |
| SCHEMBL15210572 | 0.76 | IRAK1 (0.43) | — | |
| SCHEMBL10267561 | 0.76 | MAPK1 (0.41) | EHMT2BRD4 | |
| SCHEMBL15210406 | 0.75 | IRAK4 (0.32) | SYKAURKBKCNH2KDR | |
| SCHEMBL723083 | 0.74 | TGFBR1 (0.46) | SYKKCNH2 | |
| SCHEMBL14242137 | 0.73 | SYK (0.70) | SYKAURKBKCNH2KDR | |
| SCHEMBL721675 | 0.73 | PDE4C (0.37) | SYKBRD4 | |
| SCHEMBL10266957 | 0.71 | PRKCI (0.41) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2817313-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-07 | — | — | EP | claimed |
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | US | claimed |
| EP-2817313-A1 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | claimed |
| CN-104114558-A | Furopyridine derivatives | MERCK PATENT GMBH | 2014-10-22 | — | — | CN | claimed |
| WO-2013124025-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | claimed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-2817313-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | US | disclosed |
| EP-2817313-A1 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| CN-104114558-A | Furopyridine derivatives | MERCK PATENT GMBH | 2014-10-22 | — | — | CN | disclosed |
| WO-2013124025-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013124025-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | SYK, LYN, BTK | ROCK2 520/4885ROCK1 231/4885CDC42BPB 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.